BrainCells grabs neuropsych therapy in $51M licensing pact

Just six months after gaining control of the mid-stage neuropsychiatric drug sabcomeline through an acquisition of Minster Pharmaceuticals, the UK's Proximagen has inked a deal licensing out its rights to BrainCells for up to $51 million in upfront fees and milestones. Proximagen touted its deal-making skills, but didn't break out how much it will bank from the upfront and how much is being risked on future milestones. San Diego-based BrainCells will now step in and take control of the program,...